Previous 10 | Next 10 |
1-click SPAC portfolio. Should you invest in SPACs? Should you invest in SPAK? For further details see: The First SPAC ETF - SPAK
Immatics N.V. (IMTX) has appointed Arnd Christ to succeed Thomas Ulmer as Chief Financial Officer, effective October 1, 2020.Arnd Christ was previously the CFO of InflaRx.Press release For further details see: Immatics appoints new CFO
Tuebingen, Germany and Houston, Texas, September 29, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today that Arnd Chris...
Tuebingen, Germany and Houston, Texas, September 15, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the appointment of ...
Immatics ( IMTX -0.8% ) provides an update on its fourth ACTengine cell therapy program, IMA204, designed to target COL6A3 exon 6, which is highly expressed in the stroma of various solid tumors. Preclinical data will be discussed at the Hanson Wade CAR-TCR Digital Week on Sept...
Tuebingen, Germany and Houston, Texas, Sept. 10, 2020 (GLOBE NEWSWIRE) -- IMA204 ACTengine® cell therapy program directed at novel tumor target COL6A3 exon 6 prevalently expressed at high copy numbers in tumor stroma across many solid cancers Two affinity-enhanced TCR candidate...
Immatics (NASDAQ: IMTX ) : Q2 Net loss of $23.9M. More news on: Immatics N.V., Earnings news and commentary, Read more ...
Tuebingen, Germany and Houston, TX, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Completed merger with ARYA Life Science Acquisition Corp. and subsequent NASDAQ listing with proceeds from the transaction totaling $253 million (€226 million 1 ) in July 2020. At the closing of the transa...
Tuebingen, Germany and Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial German regulatory agency, Paul-Ehrlich-Institute (PEI), granted approval to commence another clinical ACTengine® ...
Houston, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP manufacturing infrastructure at The Evelyn H. Griffin Stem Cell Therapeutics Research Laborato...
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...